M&A Deal Summary

Pharmacosmos Acquires G1 Therapeutics

On August 7, 2024, Pharmacosmos acquired life science company G1 Therapeutics for 405M USD

Acquisition Highlights
  • This is Pharmacosmos’ 2nd transaction in the Life Science sector.
  • This is Pharmacosmos’ largest (disclosed) transaction.
  • This is Pharmacosmos’ 2nd transaction in the United States.
  • This is Pharmacosmos’ 1st transaction in North Carolina.

M&A Deal Summary
Date 2024-08-07
Target G1 Therapeutics
Sector Life Science
Buyer(s) Pharmacosmos
Deal Type Add-on Acquisition
Deal Value 405M USD
Advisor(s) Centerview Partners (Financial)
Ropes & Gray
Mintz Levin Cohn Ferris Glovsky and Popeo PC (Legal)

Target

G1 Therapeutics

Research Triangle Park, North Carolina, United States
G1 Therapeutics is a commercial-stage oncology biopharmaceutical company developing and delivering next-generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA (trilaciclib). G1 Therapeutics is based in Research Triangle Park, North Carolina.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pharmacosmos

Holbaek, Denmark
Category Company
Sector Life Science
DESCRIPTION

Pharmacosmos is a specialized company focused on carbohydrate chemistry and a developer of innovative treatments for patients suffering from iron deficiency and iron deficiency anemia. Pharmacosmos is based in Holbaek, Denmark.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Add-on Acquisition) 2 of 2
State (North Carolina) 1 of 1
Country (United States) 2 of 2
Year (2024) 1 of 1
Size (of disclosed) 1 of 2
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2021-11-11 AbFero Pharmaceuticals

Boston, Massachusetts, United States

AbFero Pharmaceuticals is a clinical stage pharmaceutical company dedicated to treating diseases of iron overload. The company therapeutic platform addresses transfusional iron overload (TIO) and iron accumulation associated with diseases of aging such as age-related macular degeneration (AMD) and Parkinson's disease. AbFero Pharmaceuticals is based in Boston, Massachusetts.

Buy $225M
Mergr

Product

Company

Legal